A panelist discusses how the COAT trial showed that switching patients with uncontrolled dry eye disease on cyclosporine 0.05% to the 0.09% solution led to significant improvements in corneal staining ...
Clinicians now have an FDA-approved liquid desmopressin option for central diabetes insipidus, designed for dosing consistency across the age spectrum.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results